XOMA Royalty (XOMA) Tax Provisions (2011 - 2026)

XOMA Royalty's (XOMA) quarterly Tax Provisions came in at $1000.0 in Q1 2026, down 98.15% quarter-over-quarter from $54000.0 in Q4 2025.

XOMA Royalty (XOMA) Tax Provisions (2011 - 2026) Analysis & Trends

XOMA Royalty has disclosed Tax Provisions across 9 years of filings, most recently posting $1000.0 for Q1 2026.

Tax Provisions for Q1 2026 came in at $1000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $104000.0 (changed N/A YoY), and the FY2025 annual result was $103000.0, up 101.82% from the prior year.
Tax Provisions came in at $1000.0 for Q1 2026 at XOMA Royalty, down from $54000.0 in the prior quarter.
In the past five years, Tax Provisions ranged from a high of $54000.0 in Q4 2025 to a low of $1000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	-11.20 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-859,000.00
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	216,000.00
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	221.50 Mn
9	Abivax	95.45 Bn	95.45 Bn	-	-
10	XOMA Royalty	5.52 Mn	-60.56 Mn	-	1,000.00

Download Data